Boaz Karmazyn1, Mervyn D Cohen, Samuel Gregory Jennings, Kent A Robertson. 1. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Riley Hospital for Children, Indiana University Health, 705 Riley Hospital Drive, Rm. 1053, Indianapolis, IN 46260, USA. bkarmazy@iupui.edu
Abstract
BACKGROUND: We observed bone marrow signal changes (BMSC) in patients with plexiform neurofibromas after treatment with imatinib mesylate (Gleevec). OBJECTIVE: To evaluate the pattern and natural history of BMSC. MATERIALS AND METHODS: The data were obtained from a pilot study of imatinib mesylate in patients with plexiform neurofibromas. All patients underwent baseline and sequential whole-body STIR 1.5-T MRI after treatment. The bone marrow signal on MRI was evaluated for abnormalities, location and pattern, and any change on follow-up studies. RESULTS: The study group included 16 patients (8 males) with a median age of 14 years (range 4 to 25 years). The mean whole-body MRI follow-up duration was 1.9 years. Of the 16 patients, 14 (88%) developed BMSC. The signal change was asymmetrical in 9 of the 14 patients (64%). The appendicular skeleton was involved in all 14 patients and the axial skeleton in 3 patients (21%). BMSC was followed in 13 patients and decreased signal was seen in 9 patients (69%) after a mean duration of 1.3 years of treatment (range 0.6 to 2.9 years); no complications were observed. CONCLUSION: BMSC appeared in most patients with neurofibromatosis type 1 following treatment with imatinib mesylate. BMSC was unusually asymmetrical and involved the lower extremities. On follow-up, BMSC often showed a decrease without complications.
BACKGROUND: We observed bone marrow signal changes (BMSC) in patients with plexiform neurofibromas after treatment with imatinib mesylate (Gleevec). OBJECTIVE: To evaluate the pattern and natural history of BMSC. MATERIALS AND METHODS: The data were obtained from a pilot study of imatinib mesylate in patients with plexiform neurofibromas. All patients underwent baseline and sequential whole-body STIR 1.5-T MRI after treatment. The bone marrow signal on MRI was evaluated for abnormalities, location and pattern, and any change on follow-up studies. RESULTS: The study group included 16 patients (8 males) with a median age of 14 years (range 4 to 25 years). The mean whole-body MRI follow-up duration was 1.9 years. Of the 16 patients, 14 (88%) developed BMSC. The signal change was asymmetrical in 9 of the 14 patients (64%). The appendicular skeleton was involved in all 14 patients and the axial skeleton in 3 patients (21%). BMSC was followed in 13 patients and decreased signal was seen in 9 patients (69%) after a mean duration of 1.3 years of treatment (range 0.6 to 2.9 years); no complications were observed. CONCLUSION: BMSC appeared in most patients with neurofibromatosis type 1 following treatment with imatinib mesylate. BMSC was unusually asymmetrical and involved the lower extremities. On follow-up, BMSC often showed a decrease without complications.
Authors: Ellin Berman; Maria Nicolaides; Robert G Maki; Martin Fleisher; Suzanne Chanel; Kelly Scheu; Bri-Anne Wilson; Glenn Heller; Nicholas P Sauter Journal: N Engl J Med Date: 2006-05-11 Impact factor: 91.245
Authors: Feng-Chun Yang; David A Ingram; Shi Chen; Yuan Zhu; Jin Yuan; Xiaohong Li; Xianlin Yang; Scott Knowles; Whitney Horn; Yan Li; Shaobo Zhang; Yanzhu Yang; Saeed T Vakili; Menggang Yu; Dennis Burns; Kent Robertson; Gary Hutchins; Luis F Parada; D Wade Clapp Journal: Cell Date: 2008-10-31 Impact factor: 41.582
Authors: Marcos Duarte Guimarães; Julia Noschang; Sara Reis Teixeira; Marcel Koenigkam Santos; Henrique Manoel Lederman; Vivian Tostes; Vikas Kundra; Alex Dias Oliveira; Bruno Hochhegger; Edson Marchiori Journal: Cancer Imaging Date: 2017-02-10 Impact factor: 3.909
Authors: Shivani Ahlawat; Laura M Fayad; Muhammad Shayan Khan; Miriam A Bredella; Gordon J Harris; D Gareth Evans; Said Farschtschi; Michael A Jacobs; Avneesh Chhabra; Johannes M Salamon; Ralph Wenzel; Victor F Mautner; Eva Dombi; Wenli Cai; Scott R Plotkin; Jaishri O Blakeley Journal: Neurology Date: 2016-08-16 Impact factor: 9.910
Authors: Angelos Kaspiris; Olga D Savvidou; Elias S Vasiliadis; Argyris C Hadjimichael; Dimitra Melissaridou; Stella Iliopoulou-Kosmadaki; Ilias D Iliopoulos; Evangelia Papadimitriou; Efstathios Chronopoulos Journal: J Clin Med Date: 2022-01-15 Impact factor: 4.241